Rosai‐Dorfman disease presenting with nasal, nodal and multiple cutaneous involvements responding to a combination of systemic steroid and low‐dose thalidomide therapy

2021 ◽  
Author(s):  
Incilay Kalay Yildizhan ◽  
Hatice Sanli ◽  
Bengü Nisa Akay ◽  
Handan Merve Erol ◽  
Işınsu Kuzu ◽  
...  
Keyword(s):  
Low Dose ◽  
Systemic Steroid ◽  
Rosai Dorfman Disease

Low-dose weekly methotrexate used to treat cutaneous Rosai-Dorfman disease

2018 ◽  
Vol 43 (7) ◽  
pp. 849-851 ◽  
Author(s):  
J. J. Subash ◽  
C. Kesty ◽  
K. R. Kesty ◽  
M. Asgari ◽  
J. Jorizzo
Keyword(s):  
Low Dose ◽  
Rosai Dorfman Disease

scholarly journals Successful Treatment of Rosai-Dorfman Disease With Low-Dose Oral Thalidomide

2013 ◽  
Vol 149 (8) ◽  
pp. 992 ◽  
Author(s):  
Xiaodong Li ◽  
Yuxiao Hong ◽  
Qian An ◽  
John Chen ◽  
Huachen Wei ◽  
...  
Keyword(s):  
Successful Treatment ◽  
Low Dose ◽  
Rosai Dorfman Disease ◽  
Dose Oral

Successful treatment of Rosai-Dorfman disease with low-dose oral corticosteroid

2009 ◽  
Vol 36 (4) ◽  
pp. 237-240 ◽  
Author(s):  
Masahiro OKA ◽  
Tsuneyoshi KAMO ◽  
Noriko GOTO ◽  
Tohru NAGANO ◽  
Yuji HIRAYAMA ◽  
...  
Keyword(s):  
Successful Treatment ◽  
Low Dose ◽  
Oral Corticosteroid ◽  
Rosai Dorfman Disease ◽  
Dose Oral

Dermatoscopic findings in cutaneous Rosai-Dorfman disease and response to low-dose thalidomide

2014 ◽  
Vol 12 (4) ◽  
pp. 350-352
Author(s):  
Fang Wang ◽  
Hui Zhou ◽  
Di-Qing Luo ◽  
Jian-De Han ◽  
Mu-Kai Chen
Keyword(s):  
Low Dose ◽  
Rosai Dorfman Disease

scholarly journals Cutaneous Rosai-Dorfman Disease Successfully Treated With Low-Dose Methotrexate

2014 ◽  
Vol 150 (7) ◽  
pp. 787 ◽  
Author(s):  
Natalie Z. Sun ◽  
Jessica Galvin ◽  
Kevin D. Cooper
Keyword(s):  
Low Dose ◽  
Dose Methotrexate ◽  
Rosai Dorfman Disease

scholarly journals Long-Lasting Follow-Up with Low-Dose Steroid in an 18-Year-Old Male with Rosai–Dorfman Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Volkan Karakuş ◽  
Yelda Morgül Dere ◽  
Dilek Ersil Soysal
Keyword(s):  
Lymph Nodes ◽  
Low Dose ◽  
Plasma Cells ◽  
Oral Prednisolone ◽  
Excisional Biopsy ◽  
Steroid Treatment ◽  
Unknown Etiology ◽  
Rosai Dorfman Disease ◽  
S 100

Rosai–Dorfman disease (RDD) is a rare and benign pathology of sinus histiocytosis of unknown etiology. Lymphadenopathy is the predominant clinical manifestation, but diverse organs can also be affected. Histological features involve S-100+ histiocytes with characteristic nuclear features within the enlarged sinusoids of the lymph nodes. The clinical course is unpredictable, but is often benign with spontaneous resolution of disease in most patients. We report a patient with bilateral massive enlargement of cervical, axillary, and inguinal lymph nodes, moderately enlarged spleen, and a weight loss of 15 kg. Excisional biopsy from the cervical lymph node showed that the dilated sinusoids were infiltrated by lymphocytes, plasma cells, and large histiocytes with CD 68 and S-100 protein positive. Due to the slow progression of the disease, oral prednisolone with a body weight of 1 mg/kg was started in March 2016. The steroid dosage has been adjusted many times during the clinical follow-up. After 33 months, steroid treatment resulted in partial shrinkage of lymph nodes, the spleen returned to its normal size, and the patient gained weight. After 38 months of follow-up, no systemic symptoms, sign, or extranodal involvement were detected, and the patient continued with low-dose steroid treatment.

Rosai-Dorfman Disease Treated with Methotrexate and Low-Dose Prednisone: Case Report and Review of the Literature

2012 ◽  
Vol 16 (4) ◽  
pp. 281-285 ◽  
Author(s):  
Eiman Nasseri ◽  
Annie Belisle ◽  
Deana Funaro
Keyword(s):  
Complete Resolution ◽  
Low Dose ◽  
Rare Condition ◽  
Physical Symptoms ◽  
Vital Organ ◽  
Review Of The Literature ◽  
Rapid Improvement ◽  
Systemic Corticosteroids ◽  
Rosai Dorfman Disease ◽  
Dose Prednisone

Background: Rosai-Dorfman disease is a rare condition characterized by an accumulation of histiocytes within lymph nodes and tissue. Treatment is indicated when the condition is highly symptomatic and when widespread involvement causes vital organ compression. Objective: To review the classic physical and histologic findings in Rosai-Dorfman disease and summarize the literature supporting the use of methotrexate in this condition. Methods and Results: We describe a case of Rosai-Dorfman disease that failed to respond to monotherapy with systemic corticosteroids but improved with the addition of methotrexate. Methotrexate alone or in combination with other agents has been described in at least 12 other cases in the literature and lead to a partial or complete resolution of disease in over half of these. Conclusion: The rapid improvement of clinical and physical symptoms with minimal side effects in our case and others reinforces the utility of antimetabolites in patients with Rosai-Dorfman disease who fail to respond to corticosteroids.

Ovarian Dysfunction in Fetally Irradiated Beagles

1977 ◽  
Vol 35 ◽  
pp. 658-659
Author(s):  
T. M. Seed ◽  
M. H. Sanderson ◽  
D. L. Gutzeit ◽  
T. E. Fritz ◽  
D. V. Tolle ◽  
...  
Keyword(s):  
Gamma Rays ◽  
Low Dose ◽  
Long Term Effects ◽  
Ovarian Dysfunction ◽  
Dose Rates ◽  
Highly Sensitive ◽  
Microscopic Evaluation ◽  
Ovarian Pathology ◽  
Normal Offspring

The developing mammalian fetus is thought to be highly sensitive to ionizing radiation. However, dose, dose-rate relationships are not well established, especially the long term effects of protracted, low-dose exposure. A previous report (1) has indicated that bred beagle bitches exposed to daily doses of 5 to 35 R 60Co gamma rays throughout gestation can produce viable, seemingly normal offspring. Puppies irradiated in utero are distinguishable from controls only by their smaller size, dental abnormalities, and, in adulthood, by their inability to bear young.We report here our preliminary microscopic evaluation of ovarian pathology in young pups continuously irradiated throughout gestation at daily (22 h/day) dose rates of either 0.4, 1.0, 2.5, or 5.0 R/day of gamma rays from an attenuated 60Co source. Pups from non-irradiated bitches served as controls. Experimental animals were evaluated clinically and hematologically (control + 5.0 R/day pups) at regular intervals.

Sign in / Sign up

Export Citation Format

Share Document